Welcome to our dedicated page for Alx Oncology Holdings SEC filings (Ticker: ALXO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for ALX Oncology Holdings Inc. (Nasdaq: ALXO), a clinical-stage biotechnology company developing investigational cancer therapies. Through these filings, investors can review the company’s official disclosures on financial performance, governance, risk factors and progress of its pipeline programs, including the CD47 inhibitor evorpacept and the EGFR-targeted antibody-drug conjugate ALX2004.
Annual reports on Form 10-K and quarterly reports on Form 10-Q typically describe ALX Oncology’s research and development activities, clinical trial portfolio, expenses related to programs such as evorpacept and ALX2004, and other information relevant to its status as a clinical-stage biotechnology company. These reports also discuss risks associated with drug development, regulatory approval and financing.
Current reports on Form 8-K are used by ALX Oncology to disclose material events. For example, the company has filed 8-Ks to furnish quarterly financial results and to announce changes in its board of directors and committee composition. Such filings may incorporate press releases as exhibits and provide timely updates on corporate developments.
Investors interested in insider transactions can review Forms 3, 4 and 5, which report holdings and changes in ownership by directors, officers and certain shareholders. Proxy statements on Schedule 14A offer additional insight into governance matters and executive compensation.
On Stock Titan, ALX Oncology’s SEC filings are updated as they become available from the EDGAR system. AI-powered tools can help summarize lengthy documents, highlight key sections and clarify technical language, making it easier to understand complex topics such as clinical trial disclosures, R&D spending and risk factor discussions related to the company’s oncology pipeline.
ALX Oncology Holdings is offering 76,979,112 shares of common stock and pre-funded warrants to purchase 18,574,120 shares, for gross proceeds of $150,000,000.12 before fees. Net proceeds are estimated at $140.4 million, mainly to fund clinical development of evorpacept and ALX2004, plus working capital.
The company preliminarily estimates $48.3 million in cash, cash equivalents and investments as of December 31, 2025 and notes that, absent this raise, there would have been substantial doubt about its ability to continue as a going concern. Investors in this offering face immediate dilution of $0.33 per share based on a $1.57 offering price.
ALX Oncology Holdings Inc. entered an underwriting agreement to sell 76,979,112 shares of common stock and pre-funded warrants to purchase 18,574,120 shares, raising approximately $150 million in gross proceeds. The common stock is priced at $1.57 per share and the pre-funded warrants at $1.569 each.
The offering is fully underwritten by Piper Sandler, UBS and Wells Fargo and is expected to close on February 2, 2026, subject to customary conditions. Each pre-funded warrant has a $0.001 exercise price, can be exercised for cash or on a cashless basis, and includes ownership caps at 4.99% or 9.99%, adjustable up to 19.99% with advance notice.
ALX Oncology Holdings Inc. reported new early-stage clinical data and a preliminary year-end cash figure. The company highlighted topline findings from a Phase 1b/2 trial of its investigational CD47 inhibitor evorpacept combined with Jazz Pharmaceuticals’ ZIIHERA (zanidatamab-hrii) in heavily pretreated metastatic breast cancer patients.
In an exploratory analysis of HER2-positive metastatic breast cancer, CD47 expression appeared predictive of evorpacept activity. Separately, ALX Oncology estimated it held approximately $48.3 million in cash, cash equivalents, and short- and long-term investments as of December 31, 2025, noting this figure is unaudited, preliminary, and subject to change after completion of year-end closing procedures.
ALX Oncology Holdings Inc. reported that its Chief Financial Officer, Shantharam Harish, received a grant of stock options on January 26, 2026. The award covers 303,000 stock options with an exercise price of $1.48 per share, giving the right to buy common stock.
The options vest in 48 equal monthly installments starting on February 26, 2026, and are scheduled to expire on January 25, 2036. Following this grant, Harish beneficially owns 303,000 derivative securities directly in the form of these stock options.
ALX Oncology Holdings Inc. officer Shelly Pinto was granted 192,000 stock options on January 26, 2026. These options have an exercise price of $1.48 per share and were awarded at a cost of $0.00 to Pinto.
The options relate to ALX Oncology common stock and are held directly. They become exercisable over time, vesting in 48 equal monthly installments beginning on February 26, 2026, and are scheduled to expire on January 25, 2036 if not exercised.
ALX Oncology Holdings Inc. granted its Chief Executive Officer and director Jason Lettmann a significant stock option award. On January 26, 2026, he received an option to purchase 912,000 shares of common stock at an exercise price of $1.48 per share, expiring January 25, 2036.
The option vests in 48 equal monthly installments beginning February 26, 2026, meaning the award vests gradually over four years as long as service conditions are met. Following this grant, Lettmann beneficially owns 912,000 derivative securities directly in the form of these stock options.
ALX Oncology Holdings Inc. updated its employee compensation plans by amending its 2025 Inducement Equity Incentive Plan. Effective January 21, 2026, the board of directors reserved an additional 1,300,000 shares of common stock for issuance under this plan, bringing the total shares reserved to 2,800,000. This plan is used to grant stock options, restricted stock, restricted stock units, stock appreciation rights and performance-based awards, primarily to new hires as a material inducement to join the company. The amendment and the original plan were approved by the board without stockholder approval, consistent with Nasdaq listing rules that allow inducement awards for individuals who were not previously employees or non-employee directors, or who are rehired after a bona fide break in service.
ALX Oncology Holdings Inc. reported an insider equity award to director and 10% owner Corey S. Goodman. On January 20, 2026, Goodman received a stock option covering 40,400 shares of common stock with an exercise price of $1.32 per share, expiring on January 19, 2036.
The option vests in 12 equal monthly installments beginning on February 20, 2026, meaning the award becomes fully vested over one year. Following this transaction, Goodman beneficially owned 40,400 derivative securities directly in the form of this stock option.
ALX Oncology Holdings Inc. director receives new stock option grant. Director Garland J. Scott was awarded a stock option covering 40,400 shares of ALX Oncology common stock on January 20, 2026. The option has an exercise price of
The option vests in 12 equal monthly installments beginning on February 20, 2026, providing gradual ownership over one year, and is scheduled to expire on January 19, 2036 if not exercised.
ALX Oncology Holdings Inc. director Alan B. Sandler reported a new stock option grant for 10,100 shares of common stock. The option has an exercise price of $1.32 per share and was awarded on January 20, 2026. According to the filing, these option shares vest in 12 equal monthly installments beginning on February 20, 2026, spreading vesting over one year. The option expires on January 19, 2036, and Sandler is shown as directly holding 10,100 derivative securities following this transaction, reflecting this newly granted award.